Edition:
India

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

66.46USD
13 Dec 2019
Change (% chg)

$-0.86 (-1.28%)
Prev Close
$67.32
Open
$66.70
Day's High
$68.46
Day's Low
$65.59
Volume
620,696
Avg. Vol
558,978
52-wk High
$73.72
52-wk Low
$10.41

Latest Key Developments (Source: Significant Developments)

Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock
Wednesday, 4 Dec 2019 

Dec 4 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.ARROWHEAD PHARMACEUTICALS INC - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 4 MILLION SHARES OF ITS COMMON STOCK, OFFERED AT A PRICE OF $58.00 PER SHARE.ARROWHEAD PHARMACEUTICALS - PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 4 MILLION SHARES OF ITS COMMON STOCK, OFFERED AT PRICE OF $58.00 PER SHARE.  Full Article

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering Of Common Stock
Tuesday, 3 Dec 2019 

Dec 2 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN OFFERING OF COMMON STOCK.ARROWHEAD PHARMACEUTICALS INC - ANNOUNCED INTENTION TO OFFER AND SELL 4 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN OFFERING.  Full Article

Arrowhead Collaborator Janssen Begins Reef-1 Phase 2B Combination Study In Patients With Chronic Hepatitis B Infection
Wednesday, 28 Aug 2019 

Aug 28 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD COLLABORATOR JANSSEN BEGINS REEF-1 PHASE 2B COMBINATION STUDY IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION.ARROWHEAD PHARMACEUTICALS INC - ARROWHEAD EARNS $25 MILLION MILESTONE PAYMENT IN CONNECTION WITH TRIAL INITIATION.ARROWHEAD PHARMACEUTICALS INC - JANSSEN HAS BEGUN DOSING IN REEF-1 PHASE 2B COMBINATION STUDY IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION.  Full Article

Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease
Thursday, 27 Jun 2019 

June 27 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION FOR ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE.ARROWHEAD PHARMACEUTICALS - IS IN FINAL PREPARATIONS TO INITIATE SEQUOIA (AROAAT2001), A POTENTIALLY PIVOTAL PHASE 2/3 CLINICAL STUDY IN U.S. & EUROPE.ARROWHEAD PHARMACEUTICALS INC - IS ALSO IN FINAL PREPARATIONS TO INITIATE AROAAT2002, A PHASE 2 OPEN-LABEL CLINICAL STUDY IN EUROPE.  Full Article

Arrowhead Pharmaceuticals Inc - QTRLY Earnings Per Share $0.13
Friday, 8 Feb 2019 

Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2019 FIRST QUARTER RESULTS.ARROWHEAD PHARMACEUTICALS INC - QTRLY EARNINGS PER SHARE $0.13.ARROWHEAD PHARMACEUTICALS INC - QTRLY REVENUE $34.7 MILLION VERSUS $3.5 MILLION.  Full Article

Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT
Friday, 16 Feb 2018 

Feb 15 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT.ARROWHEAD PHARMA- U.S. FDA GRANTED ORPHAN DRUG DESIGNATION TO ARO-AAT FOR TREATMENT OF A RARE GENETIC LIVER DISEASE.  Full Article

Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF HEPATITIS B.  Full Article

Arrowhead Pharmaceuticals Reports Fiscal 2018 Q1 Results
Saturday, 10 Feb 2018 

Feb 9 (Reuters) - Arrowhead Pharmaceuticals Inc ::ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 FIRST QUARTER RESULTS.ARROWHEAD PHARMACEUTICALS INC QTRLY LOSS PER SHARE $‍0.18​.SAYS QTRLY REVENUE $3.5 MILLION VERSUS $4.4 MILLION.  Full Article

Silence Therapeutics ‍Sells Further Stake In Arrowhead Pharmaceuticals ​
Thursday, 28 Dec 2017 

Dec 28 (Reuters) - Silence Therapeutics Plc ::‍SOLD A FURTHER PART OF ITS HOLDING OF COMMON SHARES IN ARROWHEAD PHARMACEUTICALS INC.​.DEAL ‍FOR A TOTAL CONSIDERATION OF $11.3 MILLION​.  Full Article